All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

MUC13 (WO2016168607A1 Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA887973MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q9H3R2
Target Names
MUC13
Alternative Names
Down-regulated in colon cancer 1 antibody; DRCC1 antibody; FLJ20063 antibody; MUC 13 antibody; MUC-13 antibody; Muc13 antibody; MUC13 Down regulated in colon cancer 1 antibody; MUC13_HUMAN antibody; Mucin 13; cell surface associated antibody; Mucin-13 antibody; PRO20221 antibody; RECC antibody; UNQ6194 antibody
Species Reactivity
Human
Immunogen
Recombinant Human MUC13 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
In stock
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in patent WO2016168607A1, specifically targeting MUC13 (Mucin 13). MUC13 is a transmembrane glycoprotein belonging to the mucin family, predominantly expressed on epithelial cell surfaces where it plays roles in cell signaling, adhesion, and barrier function. This protein has garnered significant attention in oncology research due to its overexpression in various malignancies, including colorectal, ovarian, pancreatic, and gastric cancers, where it contributes to tumor progression, metastasis, and chemoresistance.

The reference antibody outlined in WO2016168607A1 was developed for therapeutic and diagnostic applications targeting MUC13-expressing cancers. This biosimilar antibody serves as a valuable research tool for investigating MUC13 biology, exploring its role in cancer pathogenesis, and evaluating potential therapeutic strategies. It enables researchers to study MUC13-mediated signaling pathways, assess its expression patterns in disease models, and develop novel approaches for cancer diagnosis and treatment.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

MUC13 Antibodies

MUC13 Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Epithelial and hemopoietic transmembrane mucin that may play a role in cell signaling.
Gene References into Functions
  1. The results suggest that MUC13 overexpression and loss of expression of AGR2 may predict the progression of Intraductal papillary mucinous neoplasm and an unfavorable prognosis in patients with Intraductal papillary mucinous neoplasm PMID: 29650332
  2. our study first demonstrated that USF1 could activate the transcription of MUC13, thereby enhancing the proliferation and self-renewal of glioblastoma stem cells PMID: 29441861
  3. MUC13 high expression is a novel independent adverse prognostic factor of clinical outcome in non-metastatic clear cell renal cell carcinoma patients after surgery. PMID: 27911274
  4. Luciferase assays and western blot confirmed MUC13 as a target gene of miR1323p. PMID: 28339011
  5. Results from this study demonstrate that MUC13 Functionally interacts and activates HER2 at p1248 in PDAC cells, leading to stimulation of HER2 signaling cascade, including ERK1/2, FAK, AKT and PAK1 as well as regulation of the growth, cytoskeleton remodeling and motility, invasion of PDAC cells-all collectively contributing to PDAC progression. PMID: 27321183
  6. High MUC13 expression is associated with renal cell carcinoma and drug resistance. PMID: 28205224
  7. A combination of MUC13/MUC20 expression was a potential prognostic marker for patients with ESCC, who received neoadjuvant chemotherapy followed by surgery. PMID: 26323930
  8. Results show that pancreatic ductal adenocarcinoma cells express higher levels of MUC13 and is associated with poor outcome when expressed at low level. PMID: 25672256
  9. Based on nasopharyngeal MUC13 gene expression in readily available Nasopharyngeal aspirate samples , we can discriminate between severity of disease in Respiratory syncytial virus infected infants. PMID: 25261323
  10. These results suggest miR-145 as a novel regulator of MUC13 in pancreatic cancer. PMID: 25277192
  11. Overexpression of MUC13 increased cell growth, colony formation, cell migration, and invasion in colon cancer cells. PMID: 24097071
  12. MUC13 is epigenetically regulated in ovarian cancer. PMID: 25048476
  13. Overexpression of MUC13 is associated with pancreatic neuroendocrine tumors. PMID: 24114056
  14. GALNT14 may contribute to ovarian carcinogenesis through aberrant glycosylation of MUC13. PMID: 23708057
  15. Metastatic colon cancer and liver metastasis tissue samples demonstrated significantly (p<0.05) higher cytoplasmic and nuclear MUC13 expression compared with non-metastatic colon cancer and adjacent normal colon samples. PMID: 22914648
  16. MUC13 overexpression caused a significant increase in cell motility, invasion, proliferation, and anchorage-dependent or -independent clonogenicity while decreasing cell-cell and cell-substratum adhesion in pancreatic cancer. PMID: 22027689
  17. The various functional domains of MUC13 may confer oncogenic potential to MUC13 PMID: 21450906
  18. MUC13 is a good differentiation marker for gastrointestinal mucosa PMID: 15904467
  19. Aberrant intestinal expression and allelic variant MUC13 is associated with inflammatory bowel disease. PMID: 17058067
  20. Reflux laryngitis is associated with down-regulation of mucin gene expression. PMID: 18834073
  21. Findings show the aberrant expression of MUC13 in ovarian cancer and that its expression alters the cellular characteristics of SKOV-3 cells. This implies a significant role of MUC13 in ovarian cancer. PMID: 19176398

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein. Apical cell membrane. Secreted. Note=Also exists as a soluble form.
Tissue Specificity
Highly expressed in epithelial tissues, particularly those of the gastrointestinal and respiratory tracts, such as large intestine and trachea, followed by kidney, small intestine, appendix and stomach.
Database Links

HGNC: 7511

OMIM: 612181

KEGG: hsa:56667

STRING: 9606.ENSP00000312235

UniGene: Hs.5940

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*